127 related articles for article (PubMed ID: 34091677)
1. Surgical upstaging rates in patients meeting the eligibility for active surveillance trials.
Iwamoto N; Nara M; Horiguchi SI; Aruga T
Jpn J Clin Oncol; 2021 Aug; 51(8):1219-1224. PubMed ID: 34091677
[TBL] [Abstract][Full Text] [Related]
2. Surgical Upstaging Rates for Vacuum Assisted Biopsy Proven DCIS: Implications for Active Surveillance Trials.
Grimm LJ; Ryser MD; Partridge AH; Thompson AM; Thomas JS; Wesseling J; Hwang ES
Ann Surg Oncol; 2017 Nov; 24(12):3534-3540. PubMed ID: 28795370
[TBL] [Abstract][Full Text] [Related]
3. Do Eligibility Criteria for Ductal Carcinoma In Situ (DCIS) Active Surveillance Trials Identify Patients at Low Risk for Upgrade to Invasive Carcinoma?
Oseni TO; Smith BL; Lehman CD; Vijapura CA; Pinnamaneni N; Bahl M
Ann Surg Oncol; 2020 Oct; 27(11):4459-4465. PubMed ID: 32418079
[TBL] [Abstract][Full Text] [Related]
4. Application of deep learning on mammographies to discriminate between low and high-risk DCIS for patient participation in active surveillance trials.
Alaeikhanehshir S; Voets MM; van Duijnhoven FH; Lips EH; Groen EJ; van Oirsouw MCJ; Hwang SE; Lo JY; Wesseling J; Mann RM; Teuwen J;
Cancer Imaging; 2024 Apr; 24(1):48. PubMed ID: 38576031
[TBL] [Abstract][Full Text] [Related]
5. Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?
Pilewskie M; Stempel M; Rosenfeld H; Eaton A; Van Zee KJ; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3487-3493. PubMed ID: 27172775
[TBL] [Abstract][Full Text] [Related]
6. Ductal Carcinoma In Situ - Quo Vadis?
Peltecu G
Chirurgia (Bucur); 2021 Dec; 116(5 Suppl):S5-S6. PubMed ID: 34967322
[TBL] [Abstract][Full Text] [Related]
7. Does sentinel lymph node biopsy for screening high-grade ductal carcinoma in situ of the breast cause more harm than good?
Ramzi S; Najeeb E; Coulthard J; Jenkins S
Breast Cancer Res Treat; 2020 Jul; 182(1):47-54. PubMed ID: 32430678
[TBL] [Abstract][Full Text] [Related]
8. Multicentre study of the risk of invasive cancer and use of sentinel node biopsy in women with a preoperative diagnosis of ductal carcinoma in situ.
Munck F; Clausen EW; Balslev E; Kroman N; Tvedskov TF; Holm-Rasmussen EV
Br J Surg; 2020 Jan; 107(1):96-102. PubMed ID: 31823362
[TBL] [Abstract][Full Text] [Related]
9. A model to predict upstaging to invasive carcinoma in patients preoperatively diagnosed with ductal carcinoma in situ of the breast.
Kondo T; Hayashi N; Ohde S; Suzuki K; Yoshida A; Yagata H; Niikura N; Iwamoto T; Kida K; Murai M; Takahashi Y; Tsunoda H; Nakamura S; Yamauchi H
J Surg Oncol; 2015 Oct; 112(5):476-80. PubMed ID: 26346047
[TBL] [Abstract][Full Text] [Related]
10. Women with Low-Risk DCIS Eligible for the LORIS Trial After Complete Surgical Excision: How Low Is Their Risk After Standard Therapy?
Pilewskie M; Olcese C; Patil S; Van Zee KJ
Ann Surg Oncol; 2016 Dec; 23(13):4253-4261. PubMed ID: 27766556
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of the Less Is More Approach in Treating Low-Risk Ductal Carcinoma In Situ Diagnosed on Core Needle Biopsy: Ten-Year Review of Ductal Carcinoma In Situ Upgraded to Invasion at Surgery.
Podoll MB; Reisenbichler ES; Roland L; Bruner A; Mizuguchi S; Sanders MAG
Arch Pathol Lab Med; 2018 Sep; 142(9):1120-1126. PubMed ID: 29582675
[TBL] [Abstract][Full Text] [Related]
12. Preoperatively diagnosed ductal cancers in situ of the breast presenting as even small masses are of high risk for the invasive cancer foci in postoperative specimen.
Szynglarewicz B; Kasprzak P; Halon A; Matkowski R
World J Surg Oncol; 2015 Jul; 13():218. PubMed ID: 26179898
[TBL] [Abstract][Full Text] [Related]
13. Imaging Features of Patients Undergoing Active Surveillance for Ductal Carcinoma in Situ.
Grimm LJ; Ghate SV; Hwang ES; Soo MS
Acad Radiol; 2017 Nov; 24(11):1364-1371. PubMed ID: 28705686
[TBL] [Abstract][Full Text] [Related]
14. Sentinel lymph node biopsy may be unnecessary for ductal carcinoma in situ of the breast that is small and diagnosed by preoperative biopsy.
Uemoto Y; Kondo N; Wanifuchi-Endo Y; Asano T; Hisada T; Nishikawa S; Katagiri Y; Terada M; Kato A; Okuda K; Sugiura H; Kato H; Takahashi S; Toyama T
Jpn J Clin Oncol; 2020 Dec; 50(12):1364-1369. PubMed ID: 32856072
[TBL] [Abstract][Full Text] [Related]
15. A Validated Nomogram to Predict Upstaging of Ductal Carcinoma in Situ to Invasive Disease.
Jakub JW; Murphy BL; Gonzalez AB; Conners AL; Henrichsen TL; Maimone S; Keeney MG; McLaughlin SA; Pockaj BA; Chen B; Musonza T; Harmsen WS; Boughey JC; Hieken TJ; Habermann EB; Shah HN; Degnim AC
Ann Surg Oncol; 2017 Oct; 24(10):2915-2924. PubMed ID: 28766196
[TBL] [Abstract][Full Text] [Related]
16. Ductal carcinoma in situ diagnosed by breast needle biopsy: Predictors of invasion in the excision specimen.
Doebar SC; de Monyé C; Stoop H; Rothbarth J; Willemsen SP; van Deurzen CH
Breast; 2016 Jun; 27():15-21. PubMed ID: 27212695
[TBL] [Abstract][Full Text] [Related]
17. Necessity of sentinel lymph node biopsy in ductal carcinoma in situ patients: a retrospective analysis.
Shin YD; Lee HM; Choi YJ
BMC Surg; 2021 Mar; 21(1):159. PubMed ID: 33752671
[TBL] [Abstract][Full Text] [Related]
18. Is it possible to predict underestimation in ductal carcinoma in situ of the breast? Yes, using a simple score!
Marques LC; Marta GN; de Andrade JZ; Andrade D; de Barros ACSD; Andrade FEM
Eur J Surg Oncol; 2019 Jul; 45(7):1152-1155. PubMed ID: 30665684
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with upstaging from ductal carcinoma in situ following core needle biopsy to invasive cancer in subsequent surgical excision.
Kim J; Han W; Lee JW; You JM; Shin HC; Ahn SK; Moon HG; Cho N; Moon WK; Park IA; Noh DY
Breast; 2012 Oct; 21(5):641-5. PubMed ID: 22749854
[TBL] [Abstract][Full Text] [Related]
20. Atypical ductal hyperplasia on core biopsy: an automatic trigger for excisional biopsy?
McGhan LJ; Pockaj BA; Wasif N; Giurescu ME; McCullough AE; Gray RJ
Ann Surg Oncol; 2012 Oct; 19(10):3264-9. PubMed ID: 22878619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
